Table 5 Risk factors associated with VTE on multivariate model in ovarian cancer patients receiving chemotherapy

Fotopoulou et al. [27]

Age (35–81 years): HR 1.4, 95% CI 1.1–1.8; BMI < 30 kg/m²: HR 3.2, 95% CI 2.0–5.2; FIGO IIIc or IV: HR 1.0, 95% CI 0.6–1.7; chemotherapy: HR 0.2, 95% CI 0.1–0.7; ascites: HR 1.5, 95% CI 0.9–2.3; para-aortic lymphadenectomy: HR 0.5, 95% CI 0.3–1.0; pelvic lymphadenectomy: HR 1.1, 95% CI 0.6–2.0

Fotopoulou et al. [14]

Age < 60 years: HR 1.26, 95% CI 0.58–2.71; BMI < 30 kg/m²: HR 1.07, 95% CI 0.49–2.36; ECOG: HR 0.89, 95% CI 0.42–1.87; platinum-sensitive: HR 1.16, 95% CI 0.56–2.4; serous-papillary: HR 0.64, 95% CI 0.29–1.38; ascites: HR 2.2, 95% CI 1.02–4.72; surgery: HR 0.58, 95% CI 0.24–1.36; new relapse: HR 0.64, 95% CI 0.26–1.53

Mereu et al. [28]

Age: HR 1.27, 95% CI 0.94–1.70; BMI: HR 1.62, 95% CI 1.08–2.42; FIGO stage: HR 7.14, 95% CI 0.81–62.89; histologic diagnosis: HR 0.20, 95% CI 0.05–0.78; mono-chemotherapy: HR 4.97, 95% CI 1.50–16.49; risk category: HR 2.81, 95% CI 0.88–8.96

Chavan et al. [15]

Neoadjuvant chemotherapy: RR 0.90, 95% CI 0.23–3.56; menopausal: RR 3.2, 95% CI 0.95–10.09

Zhang et al. [16]

Age > 55 years: OR 13.110, 95% CI 2.451–70.133; PLT > 300 109/L: OR 3.987, 95% CI 1.085–14.657; D-dimer > 0.5 mg/mL: OR 17.317, 95% CI 3.485–86.057; tumor diameter > 10 cm: OR 4.93, 95% CI 1.364–17.819